215 related articles for article (PubMed ID: 24416138)
1. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Aparicio J; García-Mora C; Martín M; Petriz ML; Feliu J; Sánchez-Santos ME; Ayuso JR; Fuster D; Conill C; Maurel J
PLoS One; 2014; 9(1):e82209. PubMed ID: 24416138
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
3. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Gonçalves A; Gilabert M; François E; Dahan L; Perrier H; Lamy R; Re D; Largillier R; Gasmi M; Tchiknavorian X; Esterni B; Genre D; Moureau-Zabotto L; Giovannini M; Seitz JF; Delpero JR; Turrini O; Viens P; Raoul JL
Ann Oncol; 2012 Nov; 23(11):2799-2805. PubMed ID: 22771827
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ
Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036
[TBL] [Abstract][Full Text] [Related]
6. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Kindler HL; Wroblewski K; Wallace JA; Hall MJ; Locker G; Nattam S; Agamah E; Stadler WM; Vokes EE
Invest New Drugs; 2012 Feb; 30(1):382-6. PubMed ID: 20803052
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
McGinn CJ; Zalupski MM; Shureiqi I; Robertson JM; Eckhauser FE; Smith DC; Brown D; Hejna G; Strawderman M; Normolle D; Lawrence TS
J Clin Oncol; 2001 Nov; 19(22):4202-8. PubMed ID: 11709563
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Cascinu S; Berardi R; Sobrero A; Bidoli P; Labianca R; Siena S; Ferrari D; Barni S; Aitini E; Zagonel V; Caprioni F; Villa F; Mosconi S; Faloppi L; Tonini G; Boni C; Conte P; Di Costanzo F; Cinquini M;
Dig Liver Dis; 2014 Feb; 46(2):182-6. PubMed ID: 24189171
[TBL] [Abstract][Full Text] [Related]
12. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Saif MW
Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):8-9. PubMed ID: 24322903
[No Abstract] [Full Text] [Related]
14. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Mishra G; Butler J; Ho C; Melin S; Case LD; Ennever PR; Magrinat GC; Bearden JD; Minotto DC; Howerton R; Levine E; Blackstock AW
Am J Clin Oncol; 2005 Aug; 28(4):345-50. PubMed ID: 16062075
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK; Holen KD; Schelman WR; Mulkerin DL; Deming DA; Hernan HR; Traynor AM; Goggins T; Groteluschen D; Oettel K; Robinson E; Lubner SJ
Invest New Drugs; 2013 Aug; 31(4):943-8. PubMed ID: 23263993
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
[TBL] [Abstract][Full Text] [Related]
18. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA
Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024
[TBL] [Abstract][Full Text] [Related]
20. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]